Drug Profile
Research programme: protease targeted therapeutics - Evotec SE/Ono Pharmaceutical
Latest Information Update: 27 Sep 2019
Price :
$50
*
At a glance
- Originator Evotec AG; Ono Pharmaceutical
- Developer Evotec SE; Ono Pharmaceutical
- Class Small molecules
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Unspecified